NCT00310609View on ClinicalTrials.gov

Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

October 31, 2004

Conditions
Cardiovascular Abnormalities
Interventions
DRUG

Gadopentetate dimeglumine (Magnevist)

Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY